IL245882B - Process for the preparation of n-[(3-aminooxetane-3-yl)methyl]-2-(1,1-dioxo-5,3-dihydro-4,1-benzothiazepine-4-yl)-6-methyl-quinazoline- 4-Amin - Google Patents
Process for the preparation of n-[(3-aminooxetane-3-yl)methyl]-2-(1,1-dioxo-5,3-dihydro-4,1-benzothiazepine-4-yl)-6-methyl-quinazoline- 4-AminInfo
- Publication number
- IL245882B IL245882B IL245882A IL24588216A IL245882B IL 245882 B IL245882 B IL 245882B IL 245882 A IL245882 A IL 245882A IL 24588216 A IL24588216 A IL 24588216A IL 245882 B IL245882 B IL 245882B
- Authority
- IL
- Israel
- Prior art keywords
- methyl
- aminooxetan
- benzothiazepin
- quinazolin
- dioxo
- Prior art date
Links
- -1 3-aminooxetan-3-yl Chemical group 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epoxy Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/071331 | 2014-01-24 | ||
| PCT/EP2015/051066 WO2015110446A1 (en) | 2014-01-24 | 2015-01-21 | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL245882A0 IL245882A0 (en) | 2016-08-02 |
| IL245882B true IL245882B (en) | 2019-09-26 |
Family
ID=52358790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL245882A IL245882B (en) | 2014-01-24 | 2016-05-26 | Process for the preparation of n-[(3-aminooxetane-3-yl)methyl]-2-(1,1-dioxo-5,3-dihydro-4,1-benzothiazepine-4-yl)-6-methyl-quinazoline- 4-Amin |
Country Status (20)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107635999B (zh) | 2015-05-20 | 2020-09-25 | 豪夫迈·罗氏有限公司 | 用于治疗脊髓性肌萎缩的化合物 |
| JP6779972B2 (ja) * | 2015-07-16 | 2020-11-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 呼吸器合胞体ウイルス（ｒｓｖ）感染症の処置のためのｎ−［（３−アミノ−３−オキセタニル）メチル］−２−（２，３−ジヒドロ−１，１−ジオキシド−１，４−ベンゾチアゼピン−４（５ｈ）−イル）−６−メチル−４−キナゾリンアミンの結晶形 |
| MY197231A (en) | 2015-07-22 | 2023-06-06 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
| EP4360707A3 (en) | 2015-11-12 | 2024-08-07 | F. Hoffmann-La Roche AG | Compositions for treating spinal muscular atrophy |
| KR102488323B1 (ko) | 2015-12-10 | 2023-01-12 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 또는 개선을 위한 조성물 |
| EP3386978B1 (en) | 2015-12-10 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Bridged piperidine derivatives |
| CN108017599B (zh) * | 2016-11-04 | 2020-03-03 | 上海爱科百发生物医药技术有限公司 | [3-(胺甲基)-氧杂环丁烷-3-基]氨基甲酸对甲氧基苄酯对氯苯甲酸盐合成方法 |
| EA201992878A1 (ru) | 2017-06-05 | 2020-05-08 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения болезни хантингтона |
| BR112019027719A2 (pt) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | métodos para tratar a doença de huntington |
| EP3644996B1 (en) | 2017-06-28 | 2023-07-26 | PTC Therapeutics, Inc. | Methods for treating huntington's disease |
| US11091501B2 (en) | 2017-06-30 | 2021-08-17 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| WO2019067864A1 (en) | 2017-09-29 | 2019-04-04 | Enanta Pharmaceuticals, Inc. | PHARMACEUTICAL AGENTS IN COMBINATION AS INHIBITORS OF RSV |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| HUE068060T2 (hu) | 2018-06-27 | 2024-12-28 | Ptc Therapeutics Inc | Heterociklikus és heteroaril vegyületek Huntington-kór kezelésére |
| WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| WO2020190935A1 (en) | 2019-03-18 | 2020-09-24 | Enanta Pharmaceuticals, Inc. | Benzodiazepine derivatives as rsv inhibitors |
| IL291834A (en) | 2019-10-04 | 2022-06-01 | Enanta Pharm Inc | Heterocyclic antiviral compounds |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| EP4051284A4 (en) * | 2019-10-31 | 2022-11-30 | Shanghai Ark Biopharmaceutical Co. Ltd. | RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN INHIBITOR COMPOSITIONS AND METHODS OF TREATMENT AND PROPHYLAXIS OF RSV DISEASES USING SAME |
| CN113149977A (zh) * | 2020-01-22 | 2021-07-23 | 苏州爱科百发生物医药技术有限公司 | 一类呼吸道合胞病毒抑制剂的合成与用途 |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| CN111620838A (zh) * | 2020-05-16 | 2020-09-04 | 西安都创医药科技有限公司 | 一种氯代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用 |
| CN111518055A (zh) * | 2020-05-16 | 2020-08-11 | 西安都创医药科技有限公司 | 一种苯并硫氮杂卓氧化物的制备方法及其制备的产品及其应用 |
| CN111548325A (zh) * | 2020-05-16 | 2020-08-18 | 西安都创医药科技有限公司 | 一种卤代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用 |
| CN111574475B (zh) * | 2020-06-03 | 2022-09-20 | 西安都创医药科技有限公司 | 卤代苯并硫杂卓氧化物的制备方法及其制备的产品及其应用 |
| WO2022010882A1 (en) | 2020-07-07 | 2022-01-13 | Enanta Pharmaceuticals, Inc, | Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors |
| WO2022086840A1 (en) | 2020-10-19 | 2022-04-28 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| EP4298103A4 (en) | 2021-02-26 | 2025-01-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| US12162857B2 (en) | 2022-04-27 | 2024-12-10 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
| CN119285628A (zh) * | 2023-07-10 | 2025-01-10 | 石药集团中奇制药技术（石家庄）有限公司 | 用于治疗和预防呼吸道合胞病毒感染疾病的化合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1383409A (en) * | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
| SE9901573D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
| JP2006518367A (ja) * | 2003-02-21 | 2006-08-10 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | エキソ−（ｔ−ブチル２Ｒ（＋））−２−アミノ−７−アザビシクロ［２．２．１］ヘプタン−７−カルボキシレート、中間体、およびそれらを製造および単離する方法 |
| EP1618094B1 (en) * | 2003-04-30 | 2007-09-05 | The Institutes for Pharmaceutical Discovery, LLC | Substituted heteroaryls as inhibitors of protein tyrosine phosphatases |
| DE102004045648A1 (de) * | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika zur Behandlung von Atemwegserkrankungen |
| JP4899385B2 (ja) * | 2005-09-06 | 2012-03-21 | 宇部興産株式会社 | ３−アミノメチルオキセタン化合物の製法 |
| TW201215387A (en) * | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| JP2013534233A (ja) * | 2010-08-20 | 2013-09-02 | セルゾーム リミティッド | 選択的ｊａｋ阻害剤としてのヘテロシクリルピラゾロピリミジン類似体 |
| US8871756B2 (en) * | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
| MX342153B (es) | 2011-10-11 | 2016-09-15 | Hoffmann La Roche | Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio. |
| CN105392787B (zh) * | 2013-05-14 | 2017-11-24 | 豪夫迈·罗氏有限公司 | 用于治疗和预防呼吸道合胞病毒感染的氮杂‑氧代‑吲哚 |
| JP2016518421A (ja) * | 2013-05-14 | 2016-06-23 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 呼吸器合胞体ウイルス感染症の処置および予防のためのアザ−オキソ−インドール |
-
2015
- 2015-01-20 AR ARP150100146A patent/AR099134A1/es active IP Right Grant
- 2015-01-21 CN CN201910222238.1A patent/CN109879837B/zh active Active
- 2015-01-21 RU RU2016133187A patent/RU2664643C2/ru active
- 2015-01-21 KR KR1020167020106A patent/KR101841866B1/ko active Active
- 2015-01-21 EP EP15700600.8A patent/EP3097098B1/en active Active
- 2015-01-21 SI SI201531184T patent/SI3248969T1/sl unknown
- 2015-01-21 ES ES15700600T patent/ES2788900T3/es active Active
- 2015-01-21 HR HRP20200715TT patent/HRP20200715T1/hr unknown
- 2015-01-21 SI SI201531193T patent/SI3097098T1/sl unknown
- 2015-01-21 SG SG11201605916QA patent/SG11201605916QA/en unknown
- 2015-01-21 NZ NZ721534A patent/NZ721534A/en unknown
- 2015-01-21 JP JP2016548177A patent/JP6397501B2/ja active Active
- 2015-01-21 CN CN201580005504.5A patent/CN106414436B/zh active Active
- 2015-01-21 CA CA2934225A patent/CA2934225C/en active Active
- 2015-01-21 EP EP17176794.0A patent/EP3248969B1/en active Active
- 2015-01-21 MY MYPI2016702654A patent/MY176210A/en unknown
- 2015-01-21 BR BR112016016978-6A patent/BR112016016978B1/pt active IP Right Grant
- 2015-01-21 WO PCT/EP2015/051066 patent/WO2015110446A1/en active Application Filing
- 2015-01-21 AU AU2015208244A patent/AU2015208244B2/en active Active
- 2015-01-21 ES ES17176794T patent/ES2789798T3/es active Active
- 2015-01-21 PL PL15700600T patent/PL3097098T3/pl unknown
- 2015-01-21 MX MX2016009514A patent/MX368110B/es active IP Right Grant
- 2015-01-21 PL PL17176794T patent/PL3248969T3/pl unknown
-
2016
- 2016-05-26 IL IL245882A patent/IL245882B/en active IP Right Grant
- 2016-07-21 US US15/216,501 patent/US10005770B2/en active Active
-
2018
- 2018-05-24 US US15/988,570 patent/US10253022B2/en active Active
-
2020
- 2020-03-16 AR ARP200100726A patent/AR118371A2/es unknown
- 2020-04-28 HR HRP20200680TT patent/HRP20200680T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL245882B (en) | Process for the preparation of n-[(3-aminooxetane-3-yl)methyl]-2-(1,1-dioxo-5,3-dihydro-4,1-benzothiazepine-4-yl)-6-methyl-quinazoline- 4-Amin | |
| SI3433285T1 (sl) | Izboljšan postopek za pripravo sugamadeksa | |
| IL247833B (en) | 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-converted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation | |
| ZA201606386B (en) | 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation | |
| IL259617B (en) | Methods for the preparation of 3,1-benzodioxole heterocyclic compounds | |
| ZA201706795B (en) | Process for the preparation of dicycloplatin | |
| ZA201608442B (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
| HUE036789T2 (hu) | Szintéziseljárás 1,2-benzizotiazolin-3-on elõállítására | |
| IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
| IL268835B (en) | A process for the preparation of 2-cyanoimidazole compounds | |
| SG11202005889WA (en) | Process for the preparation of methyl mercaptan | |
| ZA202004349B (en) | Fluoralkenyl compounds, process for preparation and use thereof | |
| GB2561089B (en) | Process for the preparation of 17beta-hydroxy-des-a-androst-9, 10-en-5-one | |
| EP3207041A4 (en) | An improved process for the preparation of lurasidone hydrochloride | |
| IL275480A (en) | A process for the preparation of pyrimidinyl-4-aminopyrazole compounds | |
| ZA202002116B (en) | Process for the preparation of piperine | |
| IL247895A0 (en) | Process for the preparation of n-[3-(benzylcarbamoyl)phenyl]-h1-pyrazole-5-carboxamides | |
| ZA201603729B (en) | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine | |
| IL251229B (en) | Process for preparing 5-bromo-1,2,3-trichlorobenzene | |
| IL274560A (en) | A process for the preparation of raltagravir | |
| IL247751B (en) | A method for the preparation of n-[6-(chloropyridino-3-yl)methyl]-2,2-difluoroethane-1-amine using alkylation of 2,2-difluoroethylamine | |
| GB201603886D0 (en) | Compounds for the treatment of type 2 diabetes | |
| GB201603882D0 (en) | Compounds for the treatment of type 2 diabetes | |
| HUP1500451A2 (en) | Processes for the preparation of 1,4,7-triaza-cyclononane derivatives and intermediates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |